China Health Labs is a leading provider of total lab solutions and diagnostic equipment and reagents in China. It has four business units focused on rural hospitals, military and emergency services, food safety labs, and large urban hospitals. The company has experienced strong revenue growth in recent years and has a large addressable market supported by Chinese government policies. It has proprietary technology, partnerships with government agencies, and a strategy focused on expanding into new geographic areas and developing new solutions.
This whitepaper provides an overview of Chinese pharmaceutical market access. This includes an overview of the Chinese pharmaceutical market, government regulatory bodies,distribution channels, demographics, pricing and insurance. It also includes an overview of current regulations and product registration procedures.
This paper is meant for anyone within the pharmaceutical industry who is looking to learn more about how to access the pharmaceutical market in China.
For more information, contact us for a free 15 minute consultation at http://www.pacificbridgemedical.com/contact-us/.
Presentation - New Business Models for Antibiotics: Where Are We Now? 16 Marc...Office of Health Economics
Speaking at the Superbugs & Superdrugs conference in London on 16 March 2016, OHE’s Jorge Mestre-Ferrandiz delivered a presentation on financial and collaborative incentives to accelerate clinical success for antibiotics.
Jorge discussed the economic challenges around antibiotics, and whether there is a need for a new business model. He reviewed of the impact of previous incentives, explaining what has worked in the past, and discussed possible new business models.
This whitepaper provides an overview of Chinese pharmaceutical market access. This includes an overview of the Chinese pharmaceutical market, government regulatory bodies,distribution channels, demographics, pricing and insurance. It also includes an overview of current regulations and product registration procedures.
This paper is meant for anyone within the pharmaceutical industry who is looking to learn more about how to access the pharmaceutical market in China.
For more information, contact us for a free 15 minute consultation at http://www.pacificbridgemedical.com/contact-us/.
Presentation - New Business Models for Antibiotics: Where Are We Now? 16 Marc...Office of Health Economics
Speaking at the Superbugs & Superdrugs conference in London on 16 March 2016, OHE’s Jorge Mestre-Ferrandiz delivered a presentation on financial and collaborative incentives to accelerate clinical success for antibiotics.
Jorge discussed the economic challenges around antibiotics, and whether there is a need for a new business model. He reviewed of the impact of previous incentives, explaining what has worked in the past, and discussed possible new business models.
Race against the sequencing machine: processing of raw DNA sequence data at t...Maté Ongenaert
Race against the sequencing machine: processing of raw DNA sequence data at the Genomics Core
by dr. Luc Dehaspe - Genomics Core, UZ Leuven
To grow and function, living organisms unconsciously and continuously read instructions from the DNA sequence in each cell. Thanks to the advances in DNA sequencing technology, scientists are increasingly able to consciously read along. In 2001, sequencing efforts resulted in a first draft of human genome. Since then, the capacity of the DNA reading machines has doubled every six months on average. While the first human genome sequencing project took years of worldwide collaboration, multiple genomes can now be sequenced in 10 days on a single machine at a service facility such as the Genomics Core.
Each sequencing run gives rise to a few terabytes of raw data that, using bioinformatics techniques, must be processed in time, before the next bunch of data arrives.
I will discuss bioinformatics techniques that are commonly used in the Genomics Core and that have a chance to survive another generation of sequencing machines. <\br>A crucial feature of these techniques is that they keep up with the sequencing machines by creating sub-tasks that are distributed over an extensible network of computers.
China Exit or Co-Investment Opportunities for German PE InvestorsL.E.K. Consulting
L.E.K.'s Karin von Kienlin recently presented at BVK on a study conducted by L.E.K. Munich and Shanghai. They wished to:
- Understand developments in Chinese equity investments in both the domestic China / pan-Asian market and cross-border investments between China and Germany / Europe
- Identify trends in likely future investment behavior and its drivers
- Defining success factors both for Chinese and German investors / corporates as to how to benefit from the potential opportunities of cross-border investments and cooperation
Learn more in the presentation here.
Opportunities and Challenges Associated with Novel Companion Diagnostic Techn...L.E.K. Consulting
L.E.K. Managing Director Alex Vadas spoke at a BDA workshop on "How to Mature Emerging Technologies into Companion Diagnostics?" See his presentation here.
This slidedeck details two comprehensive informatics solutions — the Biomedical Genomics Workbench and Ingenuity Knowledge Base Variant Analysis platforms. We show the intuitive user interface of CLC Cancer Research Workbench and demonstrate how the rich biological content from Ingenuity Knowledge Base helps you rapidly identify critical variants in your samples.
QIAseq Technologies for Metagenomics and Microbiome NGS Library PrepQIAGEN
In this slide deck, learn about the innovative technologies that form the basis of QIAGEN’s portfolio of QIAseq library prep solutions for metagenomics and microbiome sequencing. Whether your research starts from single microbial cells, 16s rRNA PCR amplicons, or gDNA for whole genome analysis, QIAseq technologies offer tips and tricks for capturing the genomic diversity of your samples in the most unbiased, streamlined way possible.
Next-Generation Sequencing an Intro to Tech and Applications: NGS Tech Overvi...QIAGEN
This slidedeck provides a technical overview of DNA/RNA preprocessing, template preparation, sequencing and data analysis. It covers the applications for NGS technologies, including guidelines for how to select the technology that will best address your biological question.
Introduction to Next-Generation Sequencing (NGS) TechnologyQIAGEN
The continuous evolution of NGS technology has led to an enormous diversification in NGS applications and dramatically decreased the costs to sequence a complete human genome.
In this presentation, we will discuss the following major topics:
• Basic overview of NGS sequencing technologies
• Next-generation sequencing workflow
• Spectrum of NGS applications
• QIAGEN universal NGS solutions
Lifecare is the country's premier full-service diagnostic center with laboratory, providing expertise in imaging and digital pathology services. Our integrated diagnostic services help doctors personalize patient care to optimally treat disease and maintain health and wellness. We are committed to providing only the highest level of testing quality and service and working with you to provide unique solutions to your most challenging needs. http://www.lifecareindia.com/
Wendy Mayer, VP of Worldwide Innovation at Pfizer presented this at the Health Hackathon at Cornell Tech on April 9, 2015 to the audience of Cornell, MIT, Harvard, and Weill students. #HealthHack2015
An outline of India's Medical Devices market, along with practical tips on Market Entry for Startups and SME's on navigating the complexities. For more details connect at https://ontogenix.com
Race against the sequencing machine: processing of raw DNA sequence data at t...Maté Ongenaert
Race against the sequencing machine: processing of raw DNA sequence data at the Genomics Core
by dr. Luc Dehaspe - Genomics Core, UZ Leuven
To grow and function, living organisms unconsciously and continuously read instructions from the DNA sequence in each cell. Thanks to the advances in DNA sequencing technology, scientists are increasingly able to consciously read along. In 2001, sequencing efforts resulted in a first draft of human genome. Since then, the capacity of the DNA reading machines has doubled every six months on average. While the first human genome sequencing project took years of worldwide collaboration, multiple genomes can now be sequenced in 10 days on a single machine at a service facility such as the Genomics Core.
Each sequencing run gives rise to a few terabytes of raw data that, using bioinformatics techniques, must be processed in time, before the next bunch of data arrives.
I will discuss bioinformatics techniques that are commonly used in the Genomics Core and that have a chance to survive another generation of sequencing machines. <\br>A crucial feature of these techniques is that they keep up with the sequencing machines by creating sub-tasks that are distributed over an extensible network of computers.
China Exit or Co-Investment Opportunities for German PE InvestorsL.E.K. Consulting
L.E.K.'s Karin von Kienlin recently presented at BVK on a study conducted by L.E.K. Munich and Shanghai. They wished to:
- Understand developments in Chinese equity investments in both the domestic China / pan-Asian market and cross-border investments between China and Germany / Europe
- Identify trends in likely future investment behavior and its drivers
- Defining success factors both for Chinese and German investors / corporates as to how to benefit from the potential opportunities of cross-border investments and cooperation
Learn more in the presentation here.
Opportunities and Challenges Associated with Novel Companion Diagnostic Techn...L.E.K. Consulting
L.E.K. Managing Director Alex Vadas spoke at a BDA workshop on "How to Mature Emerging Technologies into Companion Diagnostics?" See his presentation here.
This slidedeck details two comprehensive informatics solutions — the Biomedical Genomics Workbench and Ingenuity Knowledge Base Variant Analysis platforms. We show the intuitive user interface of CLC Cancer Research Workbench and demonstrate how the rich biological content from Ingenuity Knowledge Base helps you rapidly identify critical variants in your samples.
QIAseq Technologies for Metagenomics and Microbiome NGS Library PrepQIAGEN
In this slide deck, learn about the innovative technologies that form the basis of QIAGEN’s portfolio of QIAseq library prep solutions for metagenomics and microbiome sequencing. Whether your research starts from single microbial cells, 16s rRNA PCR amplicons, or gDNA for whole genome analysis, QIAseq technologies offer tips and tricks for capturing the genomic diversity of your samples in the most unbiased, streamlined way possible.
Next-Generation Sequencing an Intro to Tech and Applications: NGS Tech Overvi...QIAGEN
This slidedeck provides a technical overview of DNA/RNA preprocessing, template preparation, sequencing and data analysis. It covers the applications for NGS technologies, including guidelines for how to select the technology that will best address your biological question.
Introduction to Next-Generation Sequencing (NGS) TechnologyQIAGEN
The continuous evolution of NGS technology has led to an enormous diversification in NGS applications and dramatically decreased the costs to sequence a complete human genome.
In this presentation, we will discuss the following major topics:
• Basic overview of NGS sequencing technologies
• Next-generation sequencing workflow
• Spectrum of NGS applications
• QIAGEN universal NGS solutions
Lifecare is the country's premier full-service diagnostic center with laboratory, providing expertise in imaging and digital pathology services. Our integrated diagnostic services help doctors personalize patient care to optimally treat disease and maintain health and wellness. We are committed to providing only the highest level of testing quality and service and working with you to provide unique solutions to your most challenging needs. http://www.lifecareindia.com/
Wendy Mayer, VP of Worldwide Innovation at Pfizer presented this at the Health Hackathon at Cornell Tech on April 9, 2015 to the audience of Cornell, MIT, Harvard, and Weill students. #HealthHack2015
An outline of India's Medical Devices market, along with practical tips on Market Entry for Startups and SME's on navigating the complexities. For more details connect at https://ontogenix.com
3º FÓRUM DA SAÚDE SUPLEMENTAR - CARMELLA BOCCHINOCNseg
Palestra de Carmella Bocchino no 3º Fórum Nacional da Saúde Suplementar, realizado pela Federação Nacional de Saúde Suplementar (FenaSaúde), no Sheraton WTC São Paulo Hotel, no dia 5 de outubro de 2017.
mHealth Israel_Overview of the Healthcare System in China_Presentation by PwC...Levi Shapiro
Presentation for mHealth Israel meetup, Feb 16, 2016: How Does China Provide Healthcare for 1.4 B People? Ying Wang, PwC Israel. "Kan Bing Gui, Kan Bing Nan", means it is difficult and expensive to obtain quality healthcare in China.
Clinical Biometrics, Inc. Executive Overview
Description Clinical Biometrics is an organization dedicated to enabling predictive healthcare and disease prevention with the IoT. We are working on the IoT (Internet of Things) wireless, biomedical patient monitoring and vendor agnostic integration, pioneering programmable biosensors, integration products and services to monitor secure clinical data in real-time and over time, for inpatient and outpatient environments. Our model enables predictive and preventative healthcare delivery. We are developing vendor agnostic middleware that will allow the integration of the various vendor's sensors and protocols into a common platform with rich data analytics capabilities. This technology will impact our healthcare paradigms and usher us into the future of healthcare delivery including real-time predictive healthcare and disease prevention.
- Tim Crammer, CEO
Similar to China health presentation may 2012 (20)
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Acute scrotum is a general term referring to an emergency condition affecting the contents or the wall of the scrotum.
There are a number of conditions that present acutely, predominantly with pain and/or swelling
A careful and detailed history and examination, and in some cases, investigations allow differentiation between these diagnoses. A prompt diagnosis is essential as the patient may require urgent surgical intervention
Testicular torsion refers to twisting of the spermatic cord, causing ischaemia of the testicle.
Testicular torsion results from inadequate fixation of the testis to the tunica vaginalis producing ischemia from reduced arterial inflow and venous outflow obstruction.
The prevalence of testicular torsion in adult patients hospitalized with acute scrotal pain is approximately 25 to 50 percent
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
2. Disclaimer
Neither this presentation nor any of its contents are to be distributed to third parties without the prior written consent of China Health Labs & Diagnostics Ltd.
(“China Health Labs”). This presentation supersedes and replaces any and all material s which may have been provided to potential investors. There are certain
risks inherent in an investment in the securities of China Health Labs, which prospective investors should carefully consider before investing in the securities of
China Health Labs. Reference is made to the section entitled “Risk Factors” in the Filing Statement of China Health Labs dated August 20, 2010, which section is
incorporated by reference into this investor presentation, for a discussion of the risks inherent in an investment in the securities of China Health Labs. The Filing
Statement is available on SEDAR at www.sedar.com under China Health Labs’sprofile.
This presentation is not, and under no circumstances is it to be construed as, an advertisement or a public offering of these securities. This presentation is
personal to each offeree and does not constitute an offer to any other person or to the public generally to subscribe for or otherwise acquire any of the securities
referred to herein. No securities regulatory authority or similar authority has reviewed or in any way passed upon the presentation or the merits of these securities
and any representation to the contrary is an offence. This presentation has been prepared for information purposes only in order to assist prospective investors in
evaluating an investment in China Health Labs.
Except for the statements of historical fact, the information contained herein may be of a forward-looking nature. Such forward-looking information involves
known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement of China Health Labs to be materially
different from any future results, performance or achievements expressed or implied by statements containing forward-looking information. Although China
Health Labs has attempted to identify important factors that could cause actual results to differ materially, there may be other factors that cause results not to be
as anticipated, estimated or intended. There can be no assurance that statements containing forward looking information will prove to be accurate as actual
results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on statements
containing forward looking information.
The information contained herein includes market and industry data that has been obtained from third party sources, including industry publications, as well as
industry data prepared by China Health Labs management on the basis of its knowledge of and experience in the industry in which China Health Labs operates.
Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to
the accuracy or completeness of included data. China Health Labs believes that its industry data is accurate and that its estimates and assumptions are reasonable,
but there is no assurance as to the accuracy or completeness of this included data. Although the data is believed to be reliable, China Health Labs has not
independently verified any of the information from third party sources referred to in this presentation or ascertained the underlying economic assumptions relied
upon by such sources.
2
3. Company Overview
Leading provider of total lab solutions for medical
diagnostic and food safety in China
• We develop and sell proprietary total lab solutions to targeted sectors
and sell diagnostic equipment & reagents to large urban hospitals
• We generate revenues from the sale of solutions and equipment, and
recurring revenues from reagents and service
• We manufacture our own propriety equipment and reagents in our
Beijing facility
• 2011 revenue growth of 35% to $45.6m
• 2011 net income growth of 53% to $8.1m
3
4. China: Growing Healthcare Demand
China’s GDP per Capita (in US$)
• Rapid economic growth
• Large population
• Increasing Chinese wealth
• Growing middle class
• Decreasing birth rates
• Increasing older population
Source: The World Bank
4
5. Transitioning into Universal Healthcare
Market Oriented Healthcare China’s Healthcare Expenditure
per Capita (in US$)
• High cost of medical services
• Low government funding
• Large investment gap between urban
and rural areas
• Insufficient healthcare services in rural
areas
Out of Pocket Expenditure
(% of private health spending)
• Proactive government policies
• Government spending support
• Diversified medical insurance system
• Development of local clinics in urban
and rural areas
Universal Healthcare Source: The World Bank
5
6. Large and Growing Healthcare Market
Chinese Medical Equipment Chinese Healthcare China’s healthcare investment
Expenditure (in US$ Billions) Expenditure (in US$ Billions) over next 3 years
$125B
6
7. Competitive Advantage
• First mover in providing total lab solutions instead of individual
products
• Patented hardware and software: lab management system (LMS) is
key technology for all total lab solutions
• Extensive experience in managing labs
• Strong relations with Chinese government and customers
7
8. Chinese government policy support
Chinese government budget support
Target
Areas
Large market potential
Limited competition
8
9. Business Units
Traditional
New Business Units
Business Unit
Military &
Rural Hospitals Large Urban
Emergency Food Safety
& Clinics Hospitals & Labs
Services
• Established in 2007 • Established in 2008 • Established in 2008 • Established in 1993
• Strong revenue • Strong revenue • Strong revenue • Steady revenue
stream potential potential stream
• High margins • High margins • High margins • Low margins
• No direct • No competition • Low competition in • High competition
competition Beijing
• Dominant market • Strong market
• Dominant market position • Strong market position
position position
9
10. Rural Hospitals & Labs
• Proprietary total diagnostic lab solution
• Initial revenue from testing equipment,
800
hardware, lab management system (LMS),
installation and training
• Recurring revenue from reagents, service and
maintenance
million
• 63 mobile labs sold in Q1 2012 China’s rural population
• 906 installed or contracted to date (623 new
installations in 2011)
• Presence in Henan, Guizhou, Liaoning,
Chongqing, Hebei, Qinghai, Xinjiang and
Jilin provinces
• Only solution provider to have Chinese central
government approval
• Agreement with Biosino to expand into new
provinces and reduce reagent cost
• Developed Rural Emergency Rescue Solution
in March 2012
• Revenue increased by 144% to $6.3m
10
11. POCT for Defense and Rescue Agencies
• Point of Care Technology (POCT) integrated
with LMS
• Dry chemistry diagnostic system for use in
defense and rescue operations
• No electricity or clean water required
• Developed in cooperation with Chinese
Military
• 67 POCT field labs and 30 backpacks
delivered in 2011 Only supplier to Chinese
military and Chinese
• Signed 3 year R&D agreement with Chinese
military in Dec 2010 National Emergency
Rescue Team (NERT)
• Developed new products in March 2012,
including Type C POCT solution and BK-iED
• Revenue increased by 98% to $11.0m
11
12. Food Safety Labs
• Total food safety lab solutions integrated
with LMS
• Tests chemical or biochemical index of food
items
• Developed with Beijing municipal
government
• 17 large labs, 337 enterprise-labs and17
$1
mobile labs installed to date in Beijing
• Use “Beijing Model” as reference site to sell
to additional cities in China billion
Chinese market
• Developed new portable food safety solution, opportunity in
BK-iRT in March 2012 top 50 cities
• Revenue increased by 77% to $9.0m
12
13. Large Urban Hospitals
50%
• Medical diagnostic equipment and reagents
• Diagnosis of various blood, liver and kidney
related diseases and conditions
Percent of 1000
• Exclusive distributor for largest Chinese
hospitals served
• Initial revenue from testing equipment,
hardware, lab management system (LMS),
installation and training
• Recurring revenue from reagents,
maintenance and services
• Provides steady cash flow, lower growth and
margins than solutions business
• Revenue decreased by 6% to $19.4m
13
14. Growth Strategy
Focus on total Target growth New & improved Acquisitions &
lab solutions areas solutions partnerships
• Rural areas / Military & • Continue developing
• Provide premium • Acquisition or
Emergency / Food solutions in
value compared with partnership with
safety collaboration
individual products complementary
with customers
businesses
• Limited competition and
• Build customer loyalty
high margins • Joint R&D with Chinese
• Target established
military
• Multiple recurring brands
• Chinese government
revenue streams
support and budget • Collaboration with
• Businesses that
provincial and central
deliver high quality
government
services
14
15. R&D and Intellectual Property
• Significant focus on R&D
• 13 researchers at the R&D facility
• 19 patents filed in Beijing
• 6 granted patents • Five new products
• 78 registered trademarks • Type C POCT Diagnostic Field Lab
• BK-iED (BK Early diagnosis system for
• 13 registered copyrights cardio-cerebrovascular disease)
• 57 PRC government • BK-iRT (BK Food Safety Rapid Test
production licenses System)
• Stretcher – ICU
• Rural mobile lab (63 sold to date)
15
18. Location & Distribution
Beijing
HQ & Production Facility
Guangdong
Sales & Distribution Hub
Shanghai
Sales Office
18
19. Management
Shiping (Wilson) Yao
President, CEO, Chairman and Director
Founded Biochem Group in 1993. Over 20 years experience in the medical equipment industry. Member of China’s National Standardization
Technical Committee. Member of the Board of Renmin University of China
Judyanna Chen
CFO
Chartered Accountant and Certified Public Accountant. Articled and worked at an international accounting firm, and prior to joining the
Company, was a senior manager at Manning Elliott LLP.
Yuqiang Tang
COO, Director
Over 15 years of managerial, sales and marketing experience
Bill Tunbrant
VP of Marketing, Director
Wide range of experience in the medical equipment industry, as well as in international manufacturing. Director of Opcon AB (OMXS:OPCON),
former director of Nibe Industrier AB (OMX: NIBE’B)
Chao Zhang
VP of Finance
10 years financial management experience in the medical equipment and private health care industries
Stephen D. Wortley
Secretary
Currently a partner at the law firm McMillan LLP
19
20. Non-Executive (Independent) Directors
Yumin Zhuang
Deputy Dean of the School of Finance of Renmin University. Independent supervisor with china CITI Bank.
Hong Chang
Physician with the University Health Network in Toronto
Paul Haber
Managing Director of Haber and Co. Ltd. a company involved in capital markets and corporate advisory services. Former Director of Migao
Corporation (TSX: MGO) and Former Vice President, Chief Financial Officer and Corporate Secretary of QuStream Corporation (TSXV:QVC)
Kim Oishi
Director of Zongshen PEM Power Systems (TSX: ZPP), Former President and Director of Hanfeng Evergreen (TSX: HF), Senior Vice President of
Hanwei Energy (TSX: HE), Director of Cantronic Systems (TSX-V: CTS), and Grand Power Logistics (TSX-V: GPW)
20
21. Corporate Governance
• Timely disclosure of material information
• Dissemination of material information in accordance with all
applicable legal, regulatory and stock exchange requirements
• Disclosure Committee responsible for overseeing disclosure
practices
• Whistleblowing policy in place
• Majority of directors are independent
21
22. Investment Highlights
• Growth driven by proprietary total lab solutions
• Attractive margins due to value add for customer & limited competition
• Strong customer & government relationships due to track record of delivering
solutions
• Large and growing market supported by Chinese government budget and
policy
• Positive cash flow, with sufficient funding to continue growth in 2012
22
23. Corporate Information
TSX.V Symbol: CHO
52 Week Range: $0.40 - $1.20
Shares Outstanding: 65.6 Million
Market Capitalization (May 1, 2012): $38.7 Million
Employees: 310
23